Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −12 vs. previous quarter
- 34
- 13F valueReported value at the end of Q2 2026
- $9.07M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EVO, Q2 2026
No superinvestor reported holding EVO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Evotec SE insiders from Form 4, newest first.
No open-market purchases or sales by Evotec SE insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Evotec SE at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DCF Advisers, LLC | 1,079,024 | $3.02M | 0.79% | +13,750+1.3% | Added |
| WCM Investment Management, LLC | 671,884 | $1.88M | 0.00% | +44,624+7.1% | Added |
| Abc Arbitrage SA | 371,936 | $1.04M | 0.11% | −137,114−26.9% | Reduced |
| Optiver Holding B.V. | 322,153 | $902.0K | 0.01% | +38,577+13.6% | Added |
| Morgan Stanley | 205,763 | $576.1K | 0.00% | −53,981−20.8% | Reduced |
| LPL Financial LLC | 166,045 | $464.9K | 0.00% | +43,699+35.7% | Added |
| Envestnet Asset Management Inc | 139,596 | $390.9K | 0.00% | +20,187+16.9% | Added |
| Old Mission Capital LLC | 38,032 | $106.5K | 0.00% | +18,690+96.6% | Added |
| Pathstone Holdings, LLC | 35,779 | $100.2K | 0.00% | +1,652+4.8% | Added |
| Fore Capital, LLC | 31,355 | $87.8K | 0.12% | 00.0% | Unchanged |